Participated · Equity · May 2026

Founded in 2025 and based in Amsterdam, VNYX combines software, AI and proprietary hardware to automate complex resale workflows for returns, overstock and second-hand garments. Its current VNYX10 system processes about 10,000 items annually for partners including BOAS and Bever and has generated immediate commercial revenue. The company says it has reduced processing times from 19 minutes to 3 minutes per item and is targeting a “1-minute promise” by the end of the year. VNYX is developing a next-generation VNYX100 (100,000 items annually) scheduled for delivery to BOAS in June 2026 and is planning the VNYX1000 platform to exceed 1 million items annually. The business combines soon-to-be-patented hardware with AI-driven software and is positioning itself to help brands comply with European EPR rules and bans on destruction of goods while scaling resale operations. Having entered a post-revenue phase, VNYX has secured over €1M in strategic investments and government grants to fund R&D, product development and commercial scaling.

Participated · Grant · Oct 2022

Axelera AI is a European semiconductor company designing next-generation AI accelerators optimized for energy-efficient inference at the edge. Its Europa and Metis platforms combine custom chips with tightly integrated software, enabling customers to run AI workloads locally within strict power and thermal envelopes while preserving data privacy. The firm has shipped hardware to more than 500 customers across sectors such as defense, public safety, manufacturing, retail, agritech, robotics and security, demonstrating early commercial traction. Axelera’s edge-first architecture tackles escalating energy and cooling constraints that limit conventional data-center AI deployments, positioning the company for the projected $250 billion inference market by 2030. To drive adoption, Axelera operates a Partner Accelerator Network that unites software vendors, model makers, system integrators and solution providers, and it offers the Voyager SDK for easy workflow integration. The new capital will scale manufacturing through TSMC and Samsung, expand customer-success and ecosystem programs, and advance its software tools. Including the latest round, Axelera AI has attracted over $450 million in equity, grants and venture debt since its July 2021 incorporation, making it the most heavily funded AI chip startup in the EU.

Led · Equity · Jan 2019

Nowi is a Delft-based semiconductor company developing patented energy-harvesting power management integrated circuits (PMICs). Founded in 2015, the startup is focused on commercializing its multi-patented energy-harvesting PMIC technology for IoT, consumer and semiconductor applications. Nowi says its approach can address size and cost constraints in high-volume, low-price markets and competes with incumbents such as Texas Instruments and Analog Devices. The company planned a commercial release in 2020 and expected to launch its first NW-A2.3 Energy Harvesting PMIC in the first half of 2020. Nowi intends to grow its team, expand commercial activities, and pursue collaborations with partners on longer time horizons as it transitions from a startup to a more mature organization. The company retains a majority position following the new funding and reports a promising sales funnel and growing commercial organization. Nowi, founded in 2015 and based in Delft, develops a small patented chip that enables IoT devices to harvest ambient energy. Its core product is an Energy Harvesting technology that captures light, heat, movement and radio waves to extend or eliminate battery use. The company is translating its low-power energy-harvesting position into a market-ready chip for devices such as smart watches, sensors and asset trackers. Nowi received €1 million in funding from RVO to support commercialisation and product readiness. It previously raised €1.5 million from the Disruptive Technology Ventures fund in 2018, bringing disclosed funding to €2.5 million. CEO Simon van der Jagt says the technology aims to make IoT devices 'Plug & Forget' as the market scales toward 30 billion connected devices. Nowi develops an IoT power module technology that can power different types of sensors in different environments using a range of energy-harvesting and battery-hybrid options. The Nowi Power Module uses external energy sources as an additional means of power for small sensors. This approach enables creation of sensors that are either completely battery-less or hybrid battery sensors with greatly extended lifetimes. Led by CEO Simon van der Jagt, the company is focused on further development and commercialization of its technology. Nowi is based in Delft, The Netherlands.

Led · Debt Financing · May 2014

Lanthio Pharma applies proprietary lanthionine-peptide technology to discover and develop constrained lanthipeptide drugs with longer half-life and high receptor selectivity. Its lead program, LP2, is a peptide designed to selectively activate the Angiotensin type 2 (AT2) receptor to protect tissue from inflammation and fibrosis. LP2 is being developed for Idiopathic Pulmonary Fibrosis (IPF) with the potential to extend to renal, heart and liver fibrosis once safety and efficacy are established. The company uses a proprietary bacterial display library capability to construct and screen lanthipeptide libraries against GPCR targets. MorphoSys AG has obtained rights to commercialize Lanthio’s technology. Lanthio is funded by Inkef Capital, BioGeneration Ventures, MorphoSys and RUG Holding. The company announced a government-backed Innovation Credit loan to support development through Phase II proof-of-concept trials. Lanthio Pharma is a biopharmaceutical company focused on discovering and developing a new class of therapeutic peptides (lantipeptides) with high target selectivity and improved "drug-like" properties. Its core technology is the LanthioPepTM drug discovery platform, which can be used to identify lantipeptides. The company has signed a Technology Alliance with MorphoSys to jointly develop LanthioPepTM, with MorphoSys receiving preferred rights to exclusively license the technology for drug discovery and services. Lanthio Pharma out-licensed its lantipeptide PanCyte to Tarix Pharmaceuticals; PanCyte is expected to start clinical testing in 2013. Financially, Lanthio completed a first close of a Series A round, raising €4.8M, and the round remains open for an additional investor. The company launched in 2011 as a spin-off of the University of Groningen and is led by CEO Bart Wuurman (based in Groningen, The Netherlands).